{"transactions":[{"id":739232,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T17:01:07.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":70000,"derivative":{"exercise_price":1.14,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001746473-26-000101","document":"wk-form4_1781298064.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000174647326000101/wk-form4_1781298064.xml","form_type":"4"}},{"id":1117434,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-09T20:44:11.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000129","document":"wk-form4_1749516237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000174647325000129/wk-form4_1749516237.xml","form_type":"4"}},{"id":1476894,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2024-06-17T20:15:10.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":26764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":26764,"derivative":{"exercise_price":13.06,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":26764},"source":{"system":"sec-edgar","filing":"0001746473-24-000100","document":"wk-form4_1718669702.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000174647324000100/wk-form4_1718669702.xml","form_type":"4"}},{"id":1671856,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T17:16:03.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the \"Ordinary Shares\") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.495,"expiration_date":"2033-06-13","underlying":"Ordinary Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0000950170-24-007052","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000095017024007052/ownership.xml","form_type":"4"}},{"id":1671855,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T17:16:03.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the \"Ordinary Shares\") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.475,"expiration_date":"2032-06-06","underlying":"Ordinary Shares","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0000950170-24-007052","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000095017024007052/ownership.xml","form_type":"4"}},{"id":1851434,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T16:30:19.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares."}],"balance_after":105000,"derivative":{"exercise_price":0.495,"expiration_date":"2033-06-13","underlying":"Ordinary Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001209191-23-037906","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000120919123037906/doc4.xml","form_type":"4"}},{"id":1861799,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T17:14:08.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":14000,"derivative":{"exercise_price":23.09,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-23-035529","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000120919123035529/doc4.xml","form_type":"4"}},{"id":2224919,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T16:18:13.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters beginning October 1st and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 16, 2022 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting."}],"balance_after":15000,"derivative":{"exercise_price":6.8,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013194","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000156761922013194/doc1.xml","form_type":"4"}},{"id":2238702,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-08T16:05:46.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to this option vest upon the earlier to occur of June 7, 2023 or the date of the 2023 Annual General Meeting of the Company."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":46000,"derivative":{"exercise_price":0.4747,"expiration_date":"2032-06-06","underlying":"Ordinary Shares","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0001209191-22-035006","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000120919122035006/doc4.xml","form_type":"4"}},{"id":2649448,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-30T20:24:42.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":13286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting."}],"balance_after":13286,"derivative":{"exercise_price":28.2,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":13286},"source":{"system":"sec-edgar","filing":"0001209191-21-044172","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000120919121044172/doc4.xml","form_type":"4"}},{"id":2662941,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T17:01:04.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to this option vest upon the earlier to occur of June 16, 2022 or the date of the 2022 Annual General Meeting of the Company."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":40000,"derivative":{"exercise_price":4.79,"expiration_date":"2031-06-15","underlying":"Ordinary Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-041499","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000120919121041499/doc4.xml","form_type":"4"}},{"id":3103969,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T16:11:32.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to this option vest upon the earlier to occur of June 17, 2021 or the date of the 2021 Annual General Meeting of the Company."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":35000,"derivative":{"exercise_price":7.81,"expiration_date":"2030-06-16","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-20-037907","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574589/000120919120037907/doc4.xml","form_type":"4"}},{"id":3516683,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Performance Stock Unit","published_at":"2019-05-21T20:20:53.000Z","date":"2019-05-17","kind":"exercise","acquired":false,"shares":4688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Performance Stock Unit (PSU) granted January 30, 2017 represented a contingent right to receive one (1) share of Issuer's Common Stock. 4,688 would have vested upon the one year anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018 but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the accelateration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Performance Stock Unit (PSU) granted January 30, 2017 represented a contingent right to receive one (1) share of Issuer's Common Stock. 4,688 would have vested upon the one year anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018 but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the accelateration."}],"balance_after":0,"derivative":{"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":4688},"source":{"system":"sec-edgar","filing":"0001209191-19-031875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119031875/doc4.xml","form_type":"4"}},{"id":3516682,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Common Stock","published_at":"2019-05-21T20:20:53.000Z","date":"2019-05-20","kind":"tax_withholding","acquired":false,"shares":903,"price":28.69,"value":25907.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":101656,"source":{"system":"sec-edgar","filing":"0001209191-19-031875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119031875/doc4.xml","form_type":"4"}},{"id":3516681,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Common Stock","published_at":"2019-05-21T20:20:53.000Z","date":"2019-05-20","kind":"tax_withholding","acquired":false,"shares":2418,"price":28.69,"value":69372.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":102559,"source":{"system":"sec-edgar","filing":"0001209191-19-031875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119031875/doc4.xml","form_type":"4"}},{"id":3516680,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Common Stock","published_at":"2019-05-21T20:20:53.000Z","date":"2019-05-17","kind":"grant","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each Performance Stock Unit (PSU) granted March 29, 2018 represented a contingent right to receive one (1) share of Issuer's Common Stock. 1,750 would have vested upon the one year anniversary of the Compensation Committee's certification of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the acceleration."}],"balance_after":104977,"source":{"system":"sec-edgar","filing":"0001209191-19-031875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119031875/doc4.xml","form_type":"4"}},{"id":3516679,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Common Stock","published_at":"2019-05-21T20:20:53.000Z","date":"2019-05-17","kind":"grant","acquired":true,"shares":4688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Performance Stock Unit (PSU) granted January 30, 2017 represented a contingent right to receive one (1) share of Issuer's Common Stock. 4,688 would have vested upon the one year anniversary of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018 but vesting was accelerated under the Reporting Person's Enhanced Severance Agreement upon Reporting Person's retirement and approval of the accelateration."}],"balance_after":103227,"source":{"system":"sec-edgar","filing":"0001209191-19-031875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119031875/doc4.xml","form_type":"4"}},{"id":3611578,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Common Stock","published_at":"2019-03-05T18:16:00.000Z","date":"2019-03-04","kind":"tax_withholding","acquired":false,"shares":6446,"price":33.41,"value":215360.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":98539,"source":{"system":"sec-edgar","filing":"0001209191-19-016927","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119016927/doc4.xml","form_type":"4"}},{"id":3677154,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T17:50:24.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2019, subject to the Reporting Person's Continuous Service as of each such date."}],"balance_after":18000,"derivative":{"exercise_price":27.1,"expiration_date":"2029-01-30","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-19-006902","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119006902/doc4.xml","form_type":"4"}},{"id":3677153,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Common Stock","published_at":"2019-02-04T17:50:24.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\") in consideration of services rendered. The RSUs vest in three equal annual installments on January 31, 2020, January 31, 2021 and January 31, 2022, subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each such date."}],"balance_after":104985,"source":{"system":"sec-edgar","filing":"0001209191-19-006902","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119006902/doc4.xml","form_type":"4"}},{"id":3695433,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Common Stock","published_at":"2019-01-15T20:11:29.000Z","date":"2019-01-15","kind":"tax_withholding","acquired":false,"shares":715,"price":24.25,"value":17338.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":100485,"source":{"system":"sec-edgar","filing":"0001209191-19-003820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119003820/doc4.xml","form_type":"4"}},{"id":3695432,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP R&D"}}],"security":"Common Stock","published_at":"2019-01-15T20:11:29.000Z","date":"2019-01-12","kind":"grant","acquired":true,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Performance Stock Unit (\"PSU\") granted March 29, 2018 represented a contingent right to receive one share of Issuer's Common Stock. 1,750 PSUs vested upon on January 12, 2019 certification by the Issuer's Compensation Committee of the FDA's December 31, 2018 approval of Andexxa Gen 2 in the United States. An additional 1,750 PSUs will vest on the first anniversary of the Certification Date."}],"balance_after":101200,"source":{"system":"sec-edgar","filing":"0001209191-19-003820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919119003820/doc4.xml","form_type":"4"}},{"id":3825150,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Co-President & EVP R&D"}}],"security":"Common Stock","published_at":"2018-09-05T18:43:04.000Z","date":"2018-09-04","kind":"tax_withholding","acquired":false,"shares":8884,"price":29.1764,"value":259203.1376,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":101200,"source":{"system":"sec-edgar","filing":"0001209191-18-049647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118049647/doc4.xml","form_type":"4"}},{"id":3825149,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Co-President & EVP R&D"}}],"security":"Common Stock","published_at":"2018-09-05T18:43:04.000Z","date":"2018-08-31","kind":"exercise","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each  Performance Stock Unit (\"PSU\") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% vested on August 31, 2018."}],"balance_after":110084,"source":{"system":"sec-edgar","filing":"0001209191-18-049647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118049647/doc4.xml","form_type":"4"}},{"id":3831427,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Co-President & EVP R&D"}}],"security":"Common Stock","published_at":"2018-08-28T18:00:02.000Z","date":"2018-08-23","kind":"tax_withholding","acquired":false,"shares":8171,"price":26.05,"value":212854.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":110084,"source":{"system":"sec-edgar","filing":"0001209191-18-048722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118048722/doc4.xml","form_type":"4"}},{"id":3831426,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Co-President & EVP R&D"}}],"security":"Common Stock","published_at":"2018-08-28T18:00:02.000Z","date":"2018-07-28","kind":"exercise","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each  Performance Stock Unit (\"PSU\") granted on January 27, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 50% of the PSUs vested on July 28, 2018 and 50% will vest on August 31, 2018."}],"balance_after":118255,"source":{"system":"sec-edgar","filing":"0001209191-18-048722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118048722/doc4.xml","form_type":"4"}},{"id":3918413,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2018-05-24T20:02:20.000Z","date":"2018-05-22","kind":"tax_withholding","acquired":false,"shares":1647,"price":40.82,"value":67230.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":118255,"source":{"system":"sec-edgar","filing":"0001209191-18-033230","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118033230/doc4.xml","form_type":"4"}},{"id":3918412,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2018-05-24T20:02:20.000Z","date":"2018-05-22","kind":"grant","acquired":true,"shares":4687,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each Performance Stock Unit (\"PSU\") granted January 30, 2017 represented a contingent right to receive one share of Issuer's Common Stock. 4,687 PSUs became vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in the United States in 2018. 4,688 PSUs will vest on the first anniversary of the Certification Date."}],"balance_after":119902,"source":{"system":"sec-edgar","filing":"0001209191-18-033230","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118033230/doc4.xml","form_type":"4"}},{"id":3996125,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-14T20:17:31.000Z","date":"2018-03-12","kind":"exercise","acquired":false,"shares":5049,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":8.5,"exercise_date":"2011-03-23","expiration_date":"2021-03-22","underlying":"Common Stock","underlying_shares":5049},"source":{"system":"sec-edgar","filing":"0001209191-18-019703","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118019703/doc4.xml","form_type":"4"}},{"id":3996124,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2018-03-14T20:17:31.000Z","date":"2018-03-12","kind":"exercise","acquired":true,"shares":5049,"price":8.5,"value":42916.5,"ownership":{"direct":true},"balance_after":5049,"source":{"system":"sec-edgar","filing":"0001209191-18-019703","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118019703/doc4.xml","form_type":"4"}},{"id":4010483,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2018-03-06T17:41:25.000Z","date":"2018-03-02","kind":"tax_withholding","acquired":false,"shares":4530,"price":32.53,"value":147360.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":22499,"source":{"system":"sec-edgar","filing":"0001209191-18-017393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118017393/doc4.xml","form_type":"4"}},{"id":4078924,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-02T19:44:37.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2018, subject to the Reporting Person's Continuous Service as of each such date."}],"balance_after":35000,"derivative":{"exercise_price":51.31,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-18-007229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118007229/doc4.xml","form_type":"4"}},{"id":4078923,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2018-02-02T19:44:37.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":8750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSU\") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2018, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date."}],"balance_after":8750,"source":{"system":"sec-edgar","filing":"0001209191-18-007229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919118007229/doc4.xml","form_type":"4"}},{"id":4199053,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-09-29T18:24:40.000Z","date":"2017-09-28","kind":"exercise","acquired":false,"shares":14285,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":7,"exercise_date":"2012-03-08","expiration_date":"2022-03-07","underlying":"Common Stock","underlying_shares":14285},"source":{"system":"sec-edgar","filing":"0001209191-17-054452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117054452/doc4.xml","form_type":"4"}},{"id":4199052,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-09-29T18:24:40.000Z","date":"2017-09-28","kind":"exercise","acquired":false,"shares":6715,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5049,"derivative":{"exercise_price":8.5,"exercise_date":"2011-03-23","expiration_date":"2021-03-22","underlying":"Common Stock","underlying_shares":6715},"source":{"system":"sec-edgar","filing":"0001209191-17-054452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117054452/doc4.xml","form_type":"4"}},{"id":4199051,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-09-29T18:24:40.000Z","date":"2017-09-28","kind":"exercise","acquired":true,"shares":14285,"price":7,"value":99995.0,"ownership":{"direct":true},"balance_after":14285,"source":{"system":"sec-edgar","filing":"0001209191-17-054452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117054452/doc4.xml","form_type":"4"}},{"id":4199050,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-09-29T18:24:40.000Z","date":"2017-09-28","kind":"exercise","acquired":true,"shares":6715,"price":8.5,"value":57077.5,"ownership":{"direct":true},"balance_after":6715,"source":{"system":"sec-edgar","filing":"0001209191-17-054452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117054452/doc4.xml","form_type":"4"}},{"id":4229406,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-08-18T16:50:16.000Z","date":"2017-08-16","kind":"tax_withholding","acquired":false,"shares":2644,"price":54.86,"value":145049.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-049637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117049637/doc4.xml","form_type":"4"}},{"id":4253863,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-20T18:53:07.000Z","date":"2017-07-18","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":1918,"derivative":{"exercise_price":8.5,"exercise_date":"2011-03-23","expiration_date":"2021-03-23","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-045853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117045853/doc4.xml","form_type":"4"}},{"id":4253862,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-07-20T18:53:07.000Z","date":"2017-07-18","kind":"sale","acquired":false,"shares":10000,"price":65,"value":650000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-045853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117045853/doc4.xml","form_type":"4"}},{"id":4253861,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-07-20T18:53:07.000Z","date":"2017-07-18","kind":"exercise","acquired":true,"shares":10000,"price":8.5,"value":85000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-17-045853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117045853/doc4.xml","form_type":"4"}},{"id":4270972,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-28T17:58:40.000Z","date":"2017-06-26","kind":"exercise","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":11918,"derivative":{"exercise_price":8.5,"exercise_date":"2011-03-23","expiration_date":"2021-03-23","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-17-042166","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042166/doc4.xml","form_type":"4"}},{"id":4270971,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-06-28T17:58:40.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":10000,"price":60,"value":600000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-042166","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042166/doc4.xml","form_type":"4"}},{"id":4270970,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-06-28T17:58:40.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":3802,"price":59.33,"value":225572.66,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.96, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-17-042166","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042166/doc4.xml","form_type":"4"}},{"id":4270969,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-06-28T17:58:40.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":17954,"price":58.35,"value":1047615.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.97, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":13802,"source":{"system":"sec-edgar","filing":"0001209191-17-042166","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042166/doc4.xml","form_type":"4"}},{"id":4270968,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-06-28T17:58:40.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":10729,"price":57.24,"value":614127.96,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.96, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":31756,"source":{"system":"sec-edgar","filing":"0001209191-17-042166","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042166/doc4.xml","form_type":"4"}},{"id":4270967,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-06-28T17:58:40.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":11356,"price":56.71,"value":643998.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.99, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":42485,"source":{"system":"sec-edgar","filing":"0001209191-17-042166","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042166/doc4.xml","form_type":"4"}},{"id":4270966,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-06-28T17:58:40.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":6159,"price":55.47,"value":341639.73,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.98 to $55.94, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":53841,"source":{"system":"sec-edgar","filing":"0001209191-17-042166","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042166/doc4.xml","form_type":"4"}},{"id":4270965,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-06-28T17:58:40.000Z","date":"2017-06-26","kind":"exercise","acquired":true,"shares":60000,"price":8.5,"value":510000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001209191-17-042166","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117042166/doc4.xml","form_type":"4"}},{"id":4403292,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-03-03T17:30:06.000Z","date":"2017-03-02","kind":"tax_withholding","acquired":false,"shares":3327,"price":38.61,"value":128455.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c)."}],"balance_after":34152,"source":{"system":"sec-edgar","filing":"0001209191-17-017787","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117017787/doc4.xml","form_type":"4"}},{"id":4473361,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Performance Stock Unit","published_at":"2017-02-01T19:56:32.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follows: (i) 50% of the PSUs will become vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in either the United States or European Union (the \"Certification Date\") in 2017, with the remaining 50% vesting on the first anniversary of the Certification Date, or (ii) 37.5% of the PSUs will become vested upon the Certification Date in 2018, with the remaining 37.5% vesting on the first anniversary of the Certification Date.  If the Certification Date does not occur prior to the end of 2018, the PSUs shall not vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of Issuer's Common Stock. The PSUs vest as follows: (i) 50% of the PSUs will become vested upon the date of the Compensation Committee's certification of regulatory approval of Andexanet alfa in either the United States or European Union (the \"Certification Date\") in 2017, with the remaining 50% vesting on the first anniversary of the Certification Date, or (ii) 37.5% of the PSUs will become vested upon the Certification Date in 2018, with the remaining 37.5% vesting on the first anniversary of the Certification Date.  If the Certification Date does not occur prior to the end of 2018, the PSUs shall not vest."}],"balance_after":12500,"derivative":{"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-17-006887","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117006887/doc4.xml","form_type":"4"}},{"id":4473360,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-01T19:56:32.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 1, 2017, subject to the Reporting Person's Continuous Service as of each such date."}],"balance_after":50000,"derivative":{"exercise_price":25.54,"expiration_date":"2027-01-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-006887","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117006887/doc4.xml","form_type":"4"}},{"id":4473359,"issuer":{"id":147987,"kind":"organization","name":"PORTOLA PHARMACEUTICALS INC","symbol":"PTLA"},"owners":[{"id":38572,"kind":"person","name":"Curnutte John T","position":1,"cik":"0001574589","reported_name":"Curnutte John T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President"}}],"security":"Common Stock","published_at":"2017-02-01T19:56:32.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSU\") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2017, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001209191-17-006887","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1269021/000120919117006887/doc4.xml","form_type":"4"}}]}